U.K. cost watchdogs nix Dendreon's Provenge; GSK's Slaoui joins IAVI board;

> The U.K.'s cost watchdogs have deemed Dendreon's ($DNDN) cancer vaccine Provenge too expensive for coverage on England's National Health Service. Report

> GlaxoSmithKline ($GSK) Global Vaccines Chairman Moncef Slaoui has joined the board of directors of the International AIDS Vaccine Initiative (IAVI). Release

> Sanofi Pasteur is planning a large-scale renovation project that will include construction of a new quality control building, set to begin early this year. Report

> San Diego, CA-based biotech Polynoma has launched a Phase III trial of its melanoma vaccine candidate. More

And Finally... Influenza vaccination may protect against Guillain-Barre syndrome, a new study suggests. More (reg. req.)

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.